Alutard SQ / ALK-Abello - LARVOL DELTA

Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma (clinicaltrials.gov) - P1/2 | N=36 | Not yet recruiting | Sponsor: University of Zurich | Initiation date: May 2025 ➔ Aug 2025

Trial initiation date • Allergic Rhinitis • Allergy • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Experience with ALUTARD SQ Immunotherapy in Patients Allergic to Hymenoptera Venom (EAACI 2025) - "Two underwent SCT with Apis, both with tolerance including one patient monosensitized to Api m 10 Conclusion Alutard SQ was found to be safe both during transitions and with a build-up cluster protocol in 3 weeks, even among patients with mastocytosis. In patients who experienced re-stings, the efficacy of this treatment was confirmed."

Clinical • Immunology

Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma (clinicaltrials.gov) - P1/2 | N=36 | Not yet recruiting | Sponsor: University of Zurich

New P1/2 trial • Allergic Rhinitis • Allergy • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever (clinicaltrials.gov) - P3 | N=18 | Completed | Sponsor: Imperial College London | Unknown status ➔ Completed

Trial completion • Allergic Rhinitis • Immunology • Inflammation